Precigen to present late-breaking abstract for pivotal phase 2 study data for prgn-2012 adenoverse immunotherapy for the treatment of patients with recurrent respiratory papillomatosis at the 2024 asco annual meeting

Germantown, md. , april 24, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal phase 2 study of prgn-2012 adenoverse immunotherapy for the treatment of patients with recurrent respiratory papillomatosis (rrp) will be presented in a late-breaking oral presentation at the 2024 american society of clinical oncology (asco) annual meeting taking place from may 31 to june 4, 2024 at mccormick place in chicago, illinois.
PGEN Ratings Summary
PGEN Quant Ranking